Adicet Bio (ACET) risk factors

106 risks, 6 new, 5 dropped, 27 reworded since the prior year. Adicet restructured its workforce and added $2.3 million in severance costs while updating its clinical pipelines and regulatory timelines. The company faces new constraints regarding foreign data acceptance, AI data breaches, and China data transmission measures. Drug pricing legislative pressure increased under the Inflation Reduction Act and new tax laws like OBBBA.

105 risks. Adicet faces significant clinical and regulatory risks developing novel allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Substantial ongoing net losses, capital needs, and complex manufacturing or supply chain constraints threaten commercial viability. Operations and contractual VIE structures in China introduce severe geopolitical, regulatory, and data compliance risks.